Discovery of Mood and Therapeutic Genes in a Depression Model

This invention identifies genes that are changed in an animal model of depression and are reversed by antidepressant treatment. This approach can lead to the discovery of new biological mechanisms involved in depression and its treatment, as well as new drug targets for mood disorders.

Description

The technology uses a naturalistic animal model of depression known as unpredictable chronic mild stress (UCMS). Mice subjected to UCMS showed physical and behavioral signs of depression, which were reversed by chronic administration of either an effective antidepressant (fluoxetine) or a putative antidepressant (a CRF1 antagonist). By analyzing changes in gene expression in different brain regions of these mice, researchers identified sets of genes that are altered in the depressed state and are reversed by treatment. This approach is novel because it uses a validated model of the disease, unlike previous studies that looked at the effects of drugs in healthy animals, which may have produced misleading results not relevant to the disease itself.

Applications

- Discovering new biological mechanisms for depression and its therapeutic treatment.
- Identifying new targets for developing drugs to treat mood disorders.
- Developing new pharmacological entities.
- Neuropsychiatry research and drug development.

Advantages

- Reveals common transcriptional changes from different antidepressant treatments.
- Supports CRF1 targeting as an effective therapeutic strategy.
- Molecular impacts of antidepressants are shown to be region-specific and state-dependent.
- Suggests distinct neuronal and oligodendrocyte molecular phenotypes as candidate systems for mood regulation.

Invention Readiness

The identification of these genes serves as a proof of concept in animal models and is the first step toward developing new pharmacological entities. Further studies are needed to confirm these findings in the context of human data.

IP Status

Research Tool